Effects of first-trimester fluoxetine exposure on the newborn

https://doi.org/10.1016/S0029-7844(97)00070-7Get rights and content

Objective: To determine whether first-trimester exposure to fluoxetine, a selective serotonin reuptake inhibitor commonly used to treat depression and obsessive-compulsive disorders, is associated with increased frequency of fetal malformations.

Methods: We evaluated outcomes of all pregnancies identified prospectively with confirmed first-trimester fluoxetine exposure contained in the Eli Lilly and Company worldwide fluoxetine pregnancy registry. These outcomes were compared with historic reports of newborn surveys.

Results: Outcomes were available for 796 pregnancies, 37 from fluoxetine clinical trials and 759 from spontaneous reports. Spontaneous abortions were reported in 110 of the 796 (13.8%) pregnancies. Of the remaining 686, malformations, deformations, and disruptions, including those identified after the perinatal period, were reported in 34 (5.0%). No consistent or recurring pattern of abnormalities was observed.

Conclusion: Based on comparison with historic reports of newborn surveys, it is unlikely that maternal fluoxetine use during the first trimester of pregnancy results in increased risk of fetal malformations.

References (16)

There are more references available in the full text version of this article.

Cited by (144)

  • Maternal use of antidepressants during pregnancy and risks for adverse perinatal outcomes: a meta-analysis

    2020, Journal of Psychosomatic Research
    Citation Excerpt :

    Then, the full text of 92 articles was reviewed, 38 of which were excluded. Finally, a total of 54 studies were eligible and included in the systematic review and meta-analysis (Figure 1) [5,15–67]. Of the 54 observation studies included here, 48 5, 15-61 were cohort in design and 6 62-67 were case-control.

  • Untreated depression during pregnancy: Short- and long-term effects in offspring. A systematic review

    2017, Neuroscience
    Citation Excerpt :

    Furthermore, prenatal depression is a specific risk factor for postpartum psychosis (Ebeid et al., 2010), the most severe form of postnatal affective disorders (Gentile, 2012). On the other hand, antenatal antidepressant exposure has also been associated with poor pregnancy outcomes (Goldstein et al., 1997; Bérard et al., 2007; Gentile, 2010a; Pedersen et al., 2010), prenatal antidepressant exposure syndrome (Gentile, 2010a), and, recently, with an increased risk of autism spectrum disorder (ASD) (Gentile, 2015a). However, several studies reviewed elsewhere (Gentile, 2008, 2010b; Galbally et al., 2013) show reassuring findings.

  • Bias Against the Null Hypothesis in Retrospective Registries of Gestational Drug Exposure

    2016, Journal of Obstetrics and Gynaecology Canada
    Citation Excerpt :

    After removing all animal studies, case reports, controlled observational studies, and review articles without original data, 122 articles were reviewed in detail. Five drugs or classes of drug identified in peer-reviewed published articles fulfilled the inclusion criteria (itraconazole, fluoxetine, acyclovir, statins, and mefloquine).5,10–13 Three drugs from drug company annual reports also met the inclusion criteria (quetiapine, quadrivalent human papillomavirus vaccine, and montelukast sodium).

  • The use of antidepressant medication in pregnancy

    2014, Best Practice and Research: Clinical Obstetrics and Gynaecology
    Citation Excerpt :

    The best established end points of teratology are congenital malformations that may be indicative of a significantly disrupted fetal environment. The extant literature indicates that congenital malformations are not associated with prenatal exposure to TCAs or SSRIs [28–31], SSRIs alone [32–41], or atypical antidepressants [37,42,43]. A study of Danish women showed an increased risk of congenital malformations and SSRI prescription redemption; however, a significant number of congenital malformations were reported in women who discontinued SSRI use before pregnancy (4.5% for those that discontinued compared with 4.9% with early pregnancy exposure and 6.8% in mid- to late-exposure), which indicates that other factors may be involved [44].

View all citing articles on Scopus
View full text